Abnormal glucose metabolism leading to hyperglycaemia defines the disease of diabetes mellitus, but hyperglycaemia exists on a continuum. The levels of fasting glucose (at or above 7mmol/l) and HbA1c (at or above 48 mmol/mol or %) that are used to define the diagnosis of diabetes are chosen because they are the levels associated with the diabetes specific complication of diabetic retinopathy. Levels of glucose below these diagnostic values but above “normal” levels (. fasting glucose between 6-/l and HbA1c of 42-48 mmol/mol or 6-%) have been defined to indicate people who are at increased risk of developing type 2 diabetes. Levels of fasting glucose below 6mmol/l and HbA1c levels below 42 mmol/mol (6%) are defined as within the normal range. Successful management of diabetes with lifestyle and/or medication or transplant or bariatric surgery may result in glucose levels below those diagnostic of diabetes but, hitherto, it has not been clarified as to whether this should be termed good diabetes control, remission, resolution or cure?
The safety of montelukast sodium 4-mg and 5-mg chewable tablets in pediatric patients aged 2 to 14 years with allergic rhinitis is supported by data from studies conducted in pediatric patients aged 2 to 14 years with asthma. A safety study in pediatric patients 2 to 14 years of age with seasonal allergic rhinitis demonstrated a similar safety profile [see Adverse Reactions () ] . The safety of montelukast sodium 4-mg oral granules in pediatric patients as young as 6 months of age with perennial allergic rhinitis is supported by extrapolation from safety data obtained from studies conducted in pediatric patients 6 months to 23 months of age with asthma and from pharmacokinetic data comparing systemic exposures in patients 6 months to 23 months of age to systemic exposures in adults.